The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Imagining a Life Free from the Pain of Ankylosing Spondylitis

Imagining a Life Free from the Pain of Ankylosing Spondylitis

September 30, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dan Reynolds, lead singer of the Grammy award-winning band Imagine Dragons, has partnered with Novartis to increase awareness of ankylosing spondylitis (AS). Novartis sells the human interleukin-17A antagonist secukinumab, which has an indication for adults with:

You Might Also Like
  • Ankylosing Spondylitis Patients Report Improved Quality of Life with Bimekizumab
  • Clinical Trials Confirm Secukinumab Can Effectively Treat Ankylosing Spondylitis
  • The Bath Ankylosing Spondylitis Functional Index’s History & Patient View
Also By This Author
  • Low-Density Granulocytes Activate T Cells in SLE
  • Active ankylosing spondylitis;
  • Moderate to severe plaque psoriasis that involves large areas or many areas of the body, and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light, alone or with systemic therapy); and
  • Adults with active psoriatic arthritis.

Monster Pain
Dan Reynolds is the face of Novartis’ disease awareness campaign, Monster Pain in the AS.1 Mr. Reynolds was diagnosed with ankylosing spondylitis when he was 20 years old and has been living with the diagnosis for more than 10 years. His diagnosis was facilitated by a family history of autoimmune disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Ankylosing spondylitis entered Mr. Reynolds’ life just as his band was gaining popularity. His severe pain made it difficult to perform on stage. The diagnosis was a blow and forced him from a young age to identify strategies to help manage the pain. He relies on diet, exercise and consultation with a rheumatologist. Mr. Reynolds follows an anti-inflammatory diet, avoids red meat and consumes little to no artificial sugar. He moves and stretches regularly and emphasizes core strengthening exercises like yoga. He also notes that stress is one of the main triggers of ankylosing spondylitis. Consequently, he actively cultivates a mindset that helps him manage stress.

Diagnosis
The campaign describes ankylosing spondylitis as a “hidden condition” and points out that it affects millions of people. For many, the diagnosis is delayed. In some cases, individuals with ankylosing spondylitis are mistakenly diagnosed with rheumatoid arthritis or fibromyalgia. Novartis’ Monster Pain in the AS website offers a three-minute quiz to help visitors determine if their symptoms warrant a visit to a rheumatologist. It also provides a place where visitors may enter their zip code to discover board-certified rheumatologists in their area.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The website walks the visitor through the difference between mechanical and inflammatory back pain. It notes that, in the case of mechanical back pain, the symptoms can appear at any age and the pain can be deep and severe. The pain may also come and go and can be relieved by rest and relaxation. In many cases, mechanical back pain worsens with exercise.

In contrast, exercise tends to provide relief to inflammatory back pain. Also, unlike mechanical back pain, the first symptoms of inflammatory back pain tend to occur when patients are in their 20s and may even occur in teenagers. In addition to pain, individuals with ankylosing spondylitis experience stiffness and changes in mobility. Although specific symptoms may come and go, inflammatory back pain is chronic. Symptoms tend to worsen at night and in the morning. The website urges individuals who meet the profile of inflammatory back pain to consult with a rheumatologist if their symptoms last for three or more months. Although only 1 in 20 patients with back pain will end up with a diagnosis of ankylosing spondylitis, it is important for these patients to get the diagnosis because, if untreated, ankylosing spondylitis can cause irreversible damage including fusion of spinal joints and vertebrae.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: Ankylosing Spondylitis, AS Resource Center, Monster Pain in the AS, Novartis, plaque psoriasis, Psoriatic Arthritis, secukinumab

You Might Also Like:
  • Ankylosing Spondylitis Patients Report Improved Quality of Life with Bimekizumab
  • Clinical Trials Confirm Secukinumab Can Effectively Treat Ankylosing Spondylitis
  • The Bath Ankylosing Spondylitis Functional Index’s History & Patient View
  • Depression in Ankylosing Spondylitis: Mastery Is Key

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)